Pd17-04 Correlation of Intraprostatic Suvmax During Psma Pet/Ct and Adverse Pathology at Radical Prostatectomy

You have accessJournal of UrologyProstate Cancer: Staging I (PD17)1 May 2024PD17-04 CORRELATION OF INTRAPROSTATIC SUVMAX DURING PSMA PET/CT AND ADVERSE PATHOLOGY AT RADICAL PROSTATECTOMY Felix Preisser, Florian Nohe, Tobias Maurer, Markus Graefen, and Derya Tilki Felix PreisserFelix Preisser , Florian NoheFlorian Nohe , Tobias MaurerTobias Maurer , Markus GraefenMarkus Graefen , and Derya TilkiDerya Tilki View All Author Informationhttps://doi.org/10.1097/01.JU.0001010044.70939.31.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is a novel staging modality for prostate cancer (PCa) patients with a high positive predictive value for lesion within and outside of the prostate. To assess the ability of the maximum standardized uptake value (SUVmax) at PSMA PET/CT to predict adverse pathology at radical prostatectomy (RP). METHODS: Within a high-volume center database, we identified intermediate and high risk PCa patients who had a PSMA PET/CT with an available SUVmax inside the prostate prior to RP between 2016 and 2021. Logistic regression modeling was used to test for the ability of SUVmax to predict non-organ confined disease or adverse pathology (non-organ confined and/or Gleason ≥4+3) during RP. Kaplan-Meier analyses were used to compare biochemical recurrence (BCR)-free survival after RP stratified according to SUVmax. RESULTS: Overall, 544 patients were identified. Of those, median SUVmax in the prostate was 9.5 at PSMA PET/CT. Median PSA was 8.1 ng/ml prior RP. 50.7% vs. 49.3% of the patients had D'Amico intermediate and high-risk characteristics. Median follow-up was 24.6 months. BCR-free survival at 48 months after RP was 72.1% vs. 62.2% (p=0.03) for patients with SUVmax<9.5 vs. SUVmax ≥9.5 at PSMA PET. In logistic regression models, SUVmax (continuously coded and stratified in <9.5 vs. ≥9.5) represented an independent predictor for non-organ confined disease and adverse pathology. CONCLUSIONS: SUVmax ≥9.5 at PSMA PET/CT is an independent predictor of adverse pathology at RP. Moreover, it is associated with worse BCR-free survival after RP. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e371 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Felix Preisser More articles by this author Florian Nohe More articles by this author Tobias Maurer More articles by this author Markus Graefen More articles by this author Derya Tilki More articles by this author Expand All Advertisement PDF downloadLoading ...